ND3 SHORT- AND LONG-TERM DISABILITY BURDEN AMONG EMPLOYED PATIENTS RECEIVING DISEASE-MODIFYING TREATMENT FOR MULTIPLE SCLEROSIS.

This study examined the short-term disability (STD) and long-term disability (LTD) burden (as measures of severe productivity loss) among employees with multiple sclerosis (MS) initiating disease-modifying treatments (DMTs). Oral DMT initiators had the lowest percentage of short-term disability claims and days per long-term disability claim, suggesting productivity benefits in severe productivity loss with early access to orals. [Extracted from the article]